Tam O'Black MHIF

Tam O'Black

Vice President, Compliance, Quality & Regulatory

Tam serves as the Vice President of Compliance, Quality, and Regulatory at the Minneapolis Heart Institute Foundation. In this high-impact leadership position, Tam oversees the necessary processes, systems, and infrastructure that serve MHIF. She has deep experience in the areas of compliance, quality, contracting, and research operations.

With a law degree from William Mitchell, Tam previously held positions as Director of Research at Park Nicollet and St. Paul Heart and as Institutional Review Board Director at Park Nicollet. During a consulting practice, Tam was involved as a Special Consultant for the University of Minnesota’s Human Research Protection Program in 2016 and 2017 and has provided compliance, contracting, and operations advice to startups, health systems, universities, and industry.

Tam lives in Hopkins, Minn., has a grown son, and enjoys kayaking.

Back to Leadership Team

LinkedIn Icon





Tam O'Black MHIF
Give the Gift of Hope
4 photos of families smiling

The Minneapolis Heart Institute Foundation® (MHIF) strives to create a world without heart and vascular disease. To achieve this bold vision, we are dedicated to improving the cardiovascular health of individuals and communities through innovative research and education.

Thanks to the generosity of donors like you, we can continue this life-saving work. Please make a gift to support the area of greatest need.

Research Milestone: FDA approves device used as alternative to open-heart

blue background
Triclip team

We are honored to celebrate the culmination of years of research that has resulted in new technologies for patients! In the few last weeks, we announced a similar research milestone with the FDA approval of the TriClip system for tricuspid regurgitation. We celebrated this important milestone with local media KSTP-TV, who spotlighted the importance of this new technology. We were proud to be a leading clinical site led by Global PI Dr. Paul Sorajja and the MHIF research team who contributed significant data to the pivotal trial.